MK-2048

From Wikipedia, the free encyclopedia
Jump to: navigation, search
MK-2048
MK-2048.svg
Systematic (IUPAC) name
(6S)-2-(3-chloro-4-fluorobenzyl)-8-ethyl-10-hydroxy-N,6-dimethyl-1,9-dioxo-1,2,6,7,8,9-hexahydropyrazino‌[1′,2′:1,5]‌pyrrolo‌[2,3-d]‌pyridazine-4-carboxamide
Clinical data
Legal status Investigational
Identifiers
ATC code None
PubChem CID 11554427
ChemSpider 25058456
ChEMBL CHEMBL1237018
Chemical data
Formula C21H21ClFN5O4 
Mol. mass 461.87 g/mol

MK-2048 is a second generation integrase inhibitor, intended to be used against HIV infection. It is superior to the first available integrase inhibitor, raltegravir, in that it inhibits the HIV enzyme integrase 4 times longer. It is being investigated for use as part of pre-exposure prophylaxis (PrEP). [1]

It is being developed by Merck & Co.[2]

References[edit]

  1. ^ Keith Alcorn. Ralvetgravir shows potential for use as PrEP drug AIDSmap.com. 28 April 2009. Accessed 8 Nov 2009.
  2. ^ Mark Mascolini. Merck Offers Unique Perspective on Second-Generation Integrase Inhibitor. 10th International Workshop on Clinical Pharmacology of HIV Therapy, April 15–17, 2009, Amsterdam. Accessed 8 Nov 2009.